NORFOLK, VA – DECEMBER 23, 2009 – Genomind, LLC, a company specializing in neuropsychiatric personalized medicine, announced today a new contractual agreement with PGxL, a Louisville, KY-based molecular diagnostics laboratory. The lab will provide genetic testing for Genomind, which will offer new and unique tools to help physicians refine their clinical acumen to determine optimal treatment for patients with Treatment Resistant Depression (TRD) in order to improve standards of care.
“We are pleased to partner with PGxL, the first lab to be CLIA-certified exclusively for pharmacogenetics testing,” said Ronald I. Dozoretz, MD, Chairman and CEO of Genomind, LLC. “PGxL’s long-standing clinical expertise will allow us to achieve our goal of bringing science into the clinic and patient setting.”
Genomind, LLC is a company specializing in neuropsychiatric personalized medicine and was formed to facilitate the adoption of Personalized Medicine into psychiatry by assisting physicians in the selection of appropriate medicine based on genetic information. Genomind was founded by Ronald I. Dozoretz, MD, in 2009, and the company is advised by a group of renowned experts in the fields of human genetics and neuropsychiatric medicine. More information is available at: www.genomind.com.
About PGxL Laboratories
A privately-owned business located in Louisville, Kentucky, PGxL Laboratories was the first lab in the country CLIA-certified specifically to conduct pharmacogenetic tests. It offers pharmacogenetic testing and interpretive services, and developed one of the first commercial CYP2C9/VKORC1 tests for accurate anticoagulant dosing. Along with its clinical practice, PGxL performs contract research for manufacturers of pharmaceuticals and medical equipment. More information is available at: www.pgxlab.com.